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Herpes Zoster Vaccine to the Homebound Elderly: Prevention, Protection, and Access to Care 
Description 
As lifespans increase and the population of the United States ages, the incidence of 
herpes zoster (Hz), or shingles, will also rise.1 With the natural aging process, a decrease in 
cellular-mediated immunity produces immunosenescence where the functions of the innate and 
adaptive immune systems diminish. After initial infection with the varicella zoster virus (VZV), 
or chickenpox, the virus will lie dormant in the dorsal root ganglion of the spinal cord. Similar to 
all of the three herpes virus strains, this latent state remains until a trigger reactivates the VZV 
that causes an Hz outbreak.2 VZV can be a relatively mild disease whereas Hz tends to be a 
severe, unilateral, vesicular rash lasting 2 to 4 weeks, causing degrees of morbidity and 
mortality.3 For persons over 40 years of age in the United States, 99% have a positive serology 
of the VZV making them prone to develop Hz.4 The potential of developing shingles within 
one’s lifetime is 1 in 3 for the United States;4,5 therefore, approximately 1 million new cases of 
Hz occur each year in the United States; this incidence increases with age. The incidence for 50- 
to 59-year-olds is 5 per 1,000 cases, while the incidence for 80-year-olds and older is 11 per 
1,000 cases.6 In the United States, the aging population is projected to be greater than 70 million 
by the year 2030,7 all of whom are at high risk of developing Hz as well as experiencing 
potentially devastating complications.2 To combat these high risks in the elderly, the 10-year 
goal of Healthy People 2020 is to increase adult-vaccination rates of persons 65 years and older 
by 10%.7 
Of those who develop Hz, 10%-25% will develop peripheral herpetic neuralgia (PHN); 
the occurrence of PHN is 3 times higher in people 65 years or older.8 This condition is the most 
prevalent, painful, and long-lasting complication of Hz, consisting of severe neuropathic pain, 
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with only palliative treatment available.9 Since the risk of Hz increases with age as cell-mediated 
immunity declines, persons 80 years or older have a 25% to 50% chance of developing Hz10 and 
the presence of co-morbid diseases, stress, and depression contributes to a shingles outbreak.2,11 
With the age-related decrease in immunity, any subsequent physiologic or emotional stressors 
can trigger reactivation of the virus creating the classic, unilateral, painful vesicular rash.12 
The Shingles Prevention Study, a 5.5-year seminal study conducted by the Department of 
Veterans Affairs and completed in 2004, trialed the live attenuated Hz vaccine for the prevention 
of shingles and its complications.13 This study of 38,456 persons in 22 Veterans Affairs facilities 
provided the evidence to support Food and Drug Administration (FDA) approval for Merck’s 
Zostavax® vaccine in May 2006 for the prevention of shingles.13  Zostavax® reportedly reduced 
the incidence of an Hz outbreak by 51% and lessen the development of PHN by 67%.14 
Zostavax® was also shown to reduce the burden of illness by 61.1%, increase one’s functional 
status by 66.2%, and enhance quality of life by 55%.10 
The Centers for Disease Control and Prevention (CDC) reported that vaccination rates for 
adults in 2013 were unsatisfactorily low suggesting a public concern that was not adequately 
addressed at the local, state, and national levels.12 Zostavax® had also been under-prescribed to 
minorities,5 with administration rates reported as low as 3.9%.2 The FDA approval in 2006 
recommended Zostavax® for persons over 60 years of age with a 24% uptake of the vaccine.4 In 
2011, the uptake rate decreased to 15.8%.9 Then in 2011, the FDA recommended the age for 
Zostavax be extended to 50 years and older as the incidence in this age group (50 to 59-year-
olds) was 5 persons per 1,000.14,15 In 2018, the CDC reported that 33% of eligible adults 
received the Hz vaccine.6 No data were available specifying immunizations rates for the Hz 
vaccine in California or San Diego County where the project was conducted.  
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One of the main causes of low immunizations rates is attributed to the lack of provider 
recommendation, albeit time constraints, knowledge deficits, or personal beliefs.16 The National 
Vaccine Advisory Committee recommends registering vaccinations in individual state’s 
Immunization Information Systems (IIS) to document and track immunizations17 as a means to 
improve awareness and knowledge of required adult immunizations. 
Another major barrier for obtaining the Hz vaccine was cost and reimbursement.18 
Zostavax® is covered under Medicare Part D, a pharmacy benefit.9 In 2015, approximately 69% 
of the Medicare enrollees signed up for Medicare Part D.8 Clinicians were not able to administer 
the vaccine at the clinical appointment due to reimbursement concerns, hampering the ability to 
offer certain vaccinations.16 In 2014, the cost for Zostavax® in the United States ranged from 
$123 to $253.20 During this 4-month project, from May 2017 to August 2017, the cost for the 
Zostavax® was between $0 to $245 under Medicare Part D coverage. The out-of-pocket 
payment quoted by one Rite Aid pharmacy in San Diego was $319 (R. Cortez, personal 
communication, March 26, 2018), while Costco offered Zostavax® at $230.74 for uninsured 
customers (K. Patel, personal communication, March 26, 2018). The administration of a vaccine 
could produce a fee of up to $32 for the clinician.21,22 
Storage issues at the clinic were also seen as a barrier as the serum must be kept frozen 
with the reconstitute solution stored separately, then mixed prior to administration.14 These 
requirements make purchasing, stocking, and monitoring Zostavax® within the clinic 
cumbersome. To overcome this issue, patients obtained a prescription, picked up the vaccine 
from a pharmacy, and properly transported it back to the clinic for administration. Some 
pharmacies have registered and are capable of administering vaccines, thereby removing the 
final step.9 Nevertheless, this arduous method has been recognized as one of the barriers to 
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vaccination.16 Homebound populations have often been unable to procure the vaccine in this 
manner. Additionally, the homebound population tends to be elderly with multiple co-
morbidities. Incidents of depression, a result of high levels of daily stress, can lead to lower 
immunity reserves. All of these issues increase susceptibility to a shingles outbreak, hence the 
need for Hz vaccination in this population.2,11 One technique to reduce these barriers is to 
provide Zostavax® through a provider with a home visit.17  
Innovation 
The purpose of this 4-month project was to increase the immunization rate of Zostavax® 
administration in the homebound population 60 years of age and older by having the vaccine 
delivered and administered at home under the Medicare Part D reimbursement plan. The practice 
setting was a primary-care mobile practice providing health care to homebound persons, mostly 
elderly, with multiple co-morbid diseases. Due to co-morbidities, these patients tended to have 
extenuating circumstances that produced stress and experienced some degree of depression. All 
of these compounding factors made them highly susceptible to a shingles outbreak and the 
development of PHN. 
The low rate of adult vaccinations and high rate of protection achieved with Zostavax® 
were the main drivers for this project. An additional benefit was protection against potentially 
devastating complications, such as PHN. This project was also influenced by the Healthy People 
2020 initiative that recognized low adult vaccination rates and set a goal to increase vaccinations 
in adults by 10%.7 
The live attenuated Hz vaccine can reduce the incidence of a shingles outbreak by 70% in 
ages 50 to 59, 64% in ages 60 to 69 and 38% in ages 70 years and older.4 Additionally, the Hz 
vaccine reduces the occurrence of PHN by 66% in ages 60 years and older. Zostavax® can be 
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administered to those who have had a previous shingles outbreak2,4 or who are unsure of a 
previous chickenpox infection.5 Zostavax® remains effective for 7 to 11 years.23 With these 
positive health benefits, providing the Hz vaccine to homebound patients at higher risk for a 
shingles outbreak is a vital preventative measure. Additionally, Hz vaccination is one of the four 
Grade A adult vaccines recommended by the U.S. Preventive Services Task Force.7 The clinic’s 
EHR systems incorporated the IIS registry of California in July 2017, the second month of the 
project, which allowed previous and future vaccinations to be registered in the tracking system. 
In 2013, the cost of Hz outbreaks in the United States for persons 50 years and older was 
reportedly $5 billion (95% CI [$3.8 billion, $5.7 billion]), including both direct medical care and 
indirect costs associated with individual productivity.12 In 2006 dollars, the cost of an individual 
Hz outbreak was estimated as high as $467, including clinic visits and antiviral medications.24 
Additionally, costs associated with an Hz outbreak for other non-PHN related expenses were 
estimated between $1,158 and $11,255 for cutaneous, ophthalmic, or neuromuscular issues. 
Costs associated with PHN can be as high as $5,387 per episode. If hospitalization is required, 
the charge adds up to $7,206 in 2006 dollars. In the 12 years since then, these amounts have 
increased and do not completely reflect today’s charges or fully capture personal costs, such as 
pain, depression, anxiety, chronic fatigue, social isolation, PHN complications, or other 
extensive problems such as eye involvement including permanent vision loss.24  
Model Description 
This project was conducted through a private, home-based, primary care practice for 4 
months, May 2017 through August 2017. To qualify for the Hz vaccination, patients were first 
identified as not having been vaccinated. Further inclusion criteria included: 60 years of age or 
older, Medicare Part D coverage, a functioning refrigerator/freezer, eligibility for service with a 
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delivering pharmacy, understanding and complying with the storage requirements, and agreeing 
to be vaccinated. Exclusion criteria included: immunocompromised status, a contraindication; or 
declining the vaccine. Eligibility would be evaluated with future assessments and offered again, 
if applicable.   
Effectiveness 
The project was successful in increasing Hz vaccination rates by 473% to eligible 
patients over a 4-month period during 2-day work weeks. The project suggested that provider 
recommendations were key as well as the highest predictor for patients receiving Zostavax®.8 
Another deciding factor was monetary; the vaccine was covered by insurance or the amount of 
the co-payment was affordable.   
Of the 24 identified patents that qualified for Zostavax®, 16 received the vaccine. Six 
declined due to coverage or co-payment concerns. Two were admitted into the hospital and were 
not at home for the duration for the project. Patients with Medicare Part D coverage were offered 
Zostavax® during a routine home appointment along with an explanation of Hz, prevalence, 
complications, vaccine’s benefits, and storage requirements. An order was sent to a designated, 
delivering pharmacy where coverage was determined, then the vaccine and reconstitution were 
delivered. Upon arrival, the serum was promptly stored in the patient’s freezer. The reconstitute 
was stored in the refrigerator to enhance ease in finding both vials for administration on a return 
visit. Once administered, the vaccination was documented in the patient’s EHR chart including 
the administration data, and entry in the IIS registry. The International Classification of Diseases, 
10th revision (ICD-10) was used in the patient’s EHR, diagnostic code Z23, encounter for 
immunization.25 Likewise, the Current Procedural Terminology (CPT) code 90736 for product 
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and CPT code 90471 for administration was used in the notes, all of which allowed for the 
payment of $32 for the Zostavax® subcutaneous injection.26 
Evidence of Feasible Implementation 
The purpose of this 4-month project was to increase the immunization rate of Zostavax® 
administration to the homebound population of 60 years and older by having the vaccine 
delivered and administered in the home under the Medicare Part D reimbursement plan. The 
project produced an increase of Zostavax® immunization of 473%, but the process had several 
limitations. One limitation was the requirement that the Zostavax® serum had to be maintained 
in a frozen state and was further complicated by ensuring Zostavax® was delivered prior to the 
follow-up administration appointment. Another limitation was whether the vaccine was covered 
by insurance or the size of the co-payment; patients readily declined if Zostavax® was not 
covered at a lowest co-payment cost of $103.   
A newer version of the Hz vaccine, Shingrix®, manufactured by GlaxoSmithKline, was 
approved by the FDA on October 20, 2017 for persons 50 years and older.6 Shingrix® is a 
recombinant, adjuvanted, inactivated form of the virus containing a lyophilized surface 
glycoprotein E (gE) antigen element of the varicella virus.27 It does not require freezing as both 
the antigen and the suspension are refrigerated until time of reconstitution and administration. 
Shingrix® is reconstituted with its accompaning AS01B suspension and is an intramuscular 
injection. It requires two separate doses, 2- to 6 months apart; therefore, it poses a risk of 
complicating its full potential with the second dose. In random control trials, Shingrix® was 
found to be 97.2% effective to persons 50 years and older (95% CI [93.7%, 99.0%]) and 85.1% 
effective in persons 70 years and older (95% CI [64.5%, 94.8%]), yielding a 91.3% efficacy in 
pooled analysis for persons 70 years and older (95% CI [86.9%, 94.5%]).27 Zostavax® has been 
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shown to become less effective with age as the immune system continues to decline,4 but 
Shingrix® maintains its efficacy with aging.6 Increased provider recommendations with 
Shingrix® is anticipated as efficacy is enhanced for the higher-risk, elderly groups. Shingrix® 
can also be given to persons with or without known evidence of a VZV infection, those who 
have had a previous Hz outbreak, and immunocompetent persons. Shingrix® may also be given 
to persons with previous Zostavax® vaccinations if given at least 2 months afterwards.6 The 
major barriers of cost and coverage remain. Shingrix® is also a Medicare Part D pharmacy 
benefit. The stated cost is $194.99 per injection when not covered by insurance, making the 
Shingrix® vaccination course as much as $389.98 at Rite Aid in San Diego, CA (R. Cortez, 
personal communication, March 26, 2018). At Costco in San Diego, CA, the cost is $159.82 per 
injection, totaling $319.64 for the course without insurance benefit (K. Patel, personal 
communication, March 26, 2018). Although the cost of the Shingrix® course is slightly higher 
than the cost of one Zostavax®, Shingrix® appears to be more effective in aging populations, 
prevents more outbreaks, and should be favored over Zostavax.6 However, cost and coverage 
will continue to be a barrier. By using home care providers for access enabling the use of 
Medicare Part D coverage, vaccination and protection against shingles is possible for the 
homebound elderly population by eliminating 2 main barriers17. Utilizing home care providers 
for this growing high-risk population is a logical next-step, not only as shown in this project, but 
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